14
views
0
recommends
+1 Recommend
1 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found

      Effects of Alprenolol on Central Hemodynamics and Exercise Tolerance in Patients with Angina Pectoris

      research-article

      Read this article at

      ScienceOpenPublisher
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          The effect of alprenolol on central hemodynamics and exercise tolerance was studied in 14 patients with angina pectoris. Alprenolol decreased the heart rate and cardiac output during exercise without affecting stroke volume. The response to alprenolol was greatest in patients with normal and minimal in patients with a markedly ‘hypokinetic’ circulation. The ventricular filling pressure showed a marked increase in a few patients and a decrease in others. Alprenolol increased exercise tolerance both with respect to the onset of angina pectoris and the appearance of ST alterations on the electrocardiogram. Its primary effect seemed to be reduction in oxygen demand of the myocardium as indicated by the decrease of both heart rate and aortic systolic pressure at a given work intensity. A double-blind trial with oral treatment for a period of three weeks suggested a beneficial effect on the exercise tolerance as tested on a bicycle ergometer. Evaluation of the treatment from the patients’ symptoms alone appeared unreliable.

          Related collections

          Author and article information

          Journal
          CRD
          Cardiology
          10.1159/issn.0008-6312
          Cardiology
          S. Karger AG
          0008-6312
          1421-9751
          1973
          1973
          29 October 2008
          : 58
          : 3
          : 150-161
          Affiliations
          Laboratory of Clinical Physiology and Department of Cardiology of the Thoracic Clinics and the Medical Clinic, Karolinska Sjukhuset, Stockholm
          Article
          169629 Cardiology 1973;58:150–161
          10.1159/000169629
          db0306c9-5037-4a89-bbb7-3bea72985203
          © 1973 S. Karger AG, Basel

          Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher. Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug. Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.

          History
          Page count
          Pages: 12
          Categories
          Paper

          General medicine,Neurology,Cardiovascular Medicine,Internal medicine,Nephrology
          Exercise tolerance,Hypokinetic state,Central hemodynamics,Angina pectoris,Double-blind trial,Alprenolol

          Comments

          Comment on this article